Skip to main content
. 2022 Oct 6;10(28):10004–10016. doi: 10.12998/wjcc.v10.i28.10004

Table 4.

Protective effect of astragaloside IV on diabetes

Disease categories
Study object/model
Effect induced by autophagy
Mechanism (targets or pathways)
Ref.
Diabetic peripheral neuropathy A high-glucose medium in Schwann cells Antioxidant activity via (-) the autophagy overactivation of Schwann cells (-) Reactive oxygen species and (-) autophagy-related proteins (LC3, PINK and Parkin); protective effect (mitochondrial morphology and membrane potential) Wei et al[38]
Diabetic peripheral neuropathy High-fat diet in rats; high glucose in Schwann RSC96 cells (-) The myelin sheath injury by the apoptosis of Schwann cells via (+) autophagy (-) The activation of the PI3K/Akt/mTOR signalling pathway by (+) miR-155 expression Yin et al[41]
DN KK-Ay diabetic mice; immortalized mouse podocytes (-) Glucose-induced podocyte EMT and (+) enhanced autophagy The SIRT1–NF-κB pathway Wang et al[40]
DN STZ diabetic mice; high glucose in podocytes (-) The progression of DN via (+) autophagy induction AMPKα-promoted autophagy induction Guo et al[39]
Liver injury in diabetics Highfat diets + lowdose STZ in diabetic liver injury rats (+) Autophagy in the liver of T2DM rats; (-) IR, dyslipidaemia, oxidative stress and inflammation The promotion of AMPK/mTORmediated autophagy Zhu et al[42]

LC: Lung cancer; PINK: PTEN-induced putative kinase 1; RSC: Rat Schwann cells; KK-Ay: Spontaneous diabetes; EMT: Epithelial-mesenchymal transition; STZ: Streptozotocin; DN: Diabetic nephropathy; IR: Immunoreactive; T2DM: Type 2 diabetes mellitus.